Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High‐dose eicosapentaenoic ac...
Gespeichert in:
| Veröffentlicht in: | Clinical cardiology (Mahwah, N.J.) Jg. 40; H. 3; S. 138 - 148 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
New York
Wiley Periodicals, Inc
01.03.2017
John Wiley & Sons, Inc |
| Schlagworte: | |
| ISSN: | 0160-9289, 1932-8737, 1932-8737 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High‐dose eicosapentaenoic acid (EPA) reduces triglyceride‐rich lipoproteins without raising LDL‐C. Omega‐3s have postulated pleiotropic cardioprotective benefits beyond triglyceride‐lowering. To date, no large, multinational, randomized clinical trial has proved that lowering triglycerides on top of statin therapy improves cardiovascular outcomes. The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE‐IT; NCT01492361) is a phase 3b randomized, double‐blinded, placebo‐controlled trial of icosapent ethyl, a highly purified ethyl ester of EPA, vs placebo. The main objective is to evaluate whether treatment with icosapent ethyl reduces ischemic events in statin‐treated patients with high triglycerides at elevated cardiovascular risk. REDUCE‐IT enrolled men or women age ≥45 years with established cardiovascular disease or age ≥50 years with diabetes mellitus and 1 additional risk factor. Randomization required fasting triglycerides ≥150 mg/dL and <500 mg/dL and LDL‐C >40 mg/dL and ≤100 mg/dL with stable statin (± ezetimibe) ≥4 weeks prior to qualifying measurements. The primary endpoint is a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary endpoint is the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Several secondary, tertiary, and exploratory endpoints will be assessed. Approximately 8000 patients have been randomized at approximately 470 centers worldwide. Follow‐up will continue in this event‐driven trial until approximately 1612 adjudicated primary‐efficacy endpoint events have occurred. |
|---|---|
| AbstractList | Residual cardiovascular risk persists despite statins, yet outcome studies of lipid-targeted therapies beyond low-density lipoprotein cholesterol (LDL-C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High-dose eicosapentaenoic acid (EPA) reduces triglyceride-rich lipoproteins without raising LDL-C. Omega-3s have postulated pleiotropic cardioprotective benefits beyond triglyceride-lowering. To date, no large, multinational, randomized clinical trial has proved that lowering triglycerides on top of statin therapy improves cardiovascular outcomes. The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT; NCT01492361) is a phase 3b randomized, double-blinded, placebo-controlled trial of icosapent ethyl, a highly purified ethyl ester of EPA, vs placebo. The main objective is to evaluate whether treatment with icosapent ethyl reduces ischemic events in statin-treated patients with high triglycerides at elevated cardiovascular risk. REDUCE-IT enrolled men or women age ≥45years with established cardiovascular disease or age ≥50years with diabetes mellitus and 1 additional risk factor. Randomization required fasting triglycerides ≥150mg/dL and <500mg/dL and LDL-C >40mg/dL and ≤100mg/dL with stable statin (± ezetimibe) ≥4weeks prior to qualifying measurements. The primary endpoint is a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary endpoint is the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Several secondary, tertiary, and exploratory endpoints will be assessed. Approximately 8000 patients have been randomized at approximately 470 centers worldwide. Follow-up will continue in this event-driven trial until approximately 1612 adjudicated primary-efficacy endpoint events have occurred. Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol ( LDL ‐C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High‐dose eicosapentaenoic acid ( EPA ) reduces triglyceride‐rich lipoproteins without raising LDL ‐C. Omega‐3s have postulated pleiotropic cardioprotective benefits beyond triglyceride‐lowering. To date, no large, multinational, randomized clinical trial has proved that lowering triglycerides on top of statin therapy improves cardiovascular outcomes. The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial ( REDUCE‐IT ; NCT01492361 ) is a phase 3b randomized, double‐blinded, placebo‐controlled trial of icosapent ethyl, a highly purified ethyl ester of EPA , vs placebo. The main objective is to evaluate whether treatment with icosapent ethyl reduces ischemic events in statin‐treated patients with high triglycerides at elevated cardiovascular risk. REDUCE‐IT enrolled men or women age ≥45 years with established cardiovascular disease or age ≥50 years with diabetes mellitus and 1 additional risk factor. Randomization required fasting triglycerides ≥150 mg/ dL and <500 mg/ dL and LDL ‐C >40 mg/ dL and ≤100 mg/ dL with stable statin (± ezetimibe) ≥4 weeks prior to qualifying measurements. The primary endpoint is a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary endpoint is the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Several secondary, tertiary, and exploratory endpoints will be assessed. Approximately 8000 patients have been randomized at approximately 470 centers worldwide. Follow‐up will continue in this event‐driven trial until approximately 1612 adjudicated primary‐efficacy endpoint events have occurred. Residual cardiovascular risk persists despite statins, yet outcome studies of lipid-targeted therapies beyond low-density lipoprotein cholesterol (LDL-C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High-dose eicosapentaenoic acid (EPA) reduces triglyceride-rich lipoproteins without raising LDL-C. Omega-3s have postulated pleiotropic cardioprotective benefits beyond triglyceride-lowering. To date, no large, multinational, randomized clinical trial has proved that lowering triglycerides on top of statin therapy improves cardiovascular outcomes. The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT; NCT01492361) is a phase 3b randomized, double-blinded, placebo-controlled trial of icosapent ethyl, a highly purified ethyl ester of EPA, vs placebo. The main objective is to evaluate whether treatment with icosapent ethyl reduces ischemic events in statin-treated patients with high triglycerides at elevated cardiovascular risk. REDUCE-IT enrolled men or women age ≥45 years with established cardiovascular disease or age ≥50 years with diabetes mellitus and 1 additional risk factor. Randomization required fasting triglycerides ≥150 mg/dL and <500 mg/dL and LDL-C >40 mg/dL and ≤100 mg/dL with stable statin (± ezetimibe) ≥4 weeks prior to qualifying measurements. The primary endpoint is a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary endpoint is the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Several secondary, tertiary, and exploratory endpoints will be assessed. Approximately 8000 patients have been randomized at approximately 470 centers worldwide. Follow-up will continue in this event-driven trial until approximately 1612 adjudicated primary-efficacy endpoint events have occurred.Residual cardiovascular risk persists despite statins, yet outcome studies of lipid-targeted therapies beyond low-density lipoprotein cholesterol (LDL-C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High-dose eicosapentaenoic acid (EPA) reduces triglyceride-rich lipoproteins without raising LDL-C. Omega-3s have postulated pleiotropic cardioprotective benefits beyond triglyceride-lowering. To date, no large, multinational, randomized clinical trial has proved that lowering triglycerides on top of statin therapy improves cardiovascular outcomes. The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT; NCT01492361) is a phase 3b randomized, double-blinded, placebo-controlled trial of icosapent ethyl, a highly purified ethyl ester of EPA, vs placebo. The main objective is to evaluate whether treatment with icosapent ethyl reduces ischemic events in statin-treated patients with high triglycerides at elevated cardiovascular risk. REDUCE-IT enrolled men or women age ≥45 years with established cardiovascular disease or age ≥50 years with diabetes mellitus and 1 additional risk factor. Randomization required fasting triglycerides ≥150 mg/dL and <500 mg/dL and LDL-C >40 mg/dL and ≤100 mg/dL with stable statin (± ezetimibe) ≥4 weeks prior to qualifying measurements. The primary endpoint is a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary endpoint is the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Several secondary, tertiary, and exploratory endpoints will be assessed. Approximately 8000 patients have been randomized at approximately 470 centers worldwide. Follow-up will continue in this event-driven trial until approximately 1612 adjudicated primary-efficacy endpoint events have occurred. Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High‐dose eicosapentaenoic acid (EPA) reduces triglyceride‐rich lipoproteins without raising LDL‐C. Omega‐3s have postulated pleiotropic cardioprotective benefits beyond triglyceride‐lowering. To date, no large, multinational, randomized clinical trial has proved that lowering triglycerides on top of statin therapy improves cardiovascular outcomes. The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE‐IT; NCT01492361) is a phase 3b randomized, double‐blinded, placebo‐controlled trial of icosapent ethyl, a highly purified ethyl ester of EPA, vs placebo. The main objective is to evaluate whether treatment with icosapent ethyl reduces ischemic events in statin‐treated patients with high triglycerides at elevated cardiovascular risk. REDUCE‐IT enrolled men or women age ≥45 years with established cardiovascular disease or age ≥50 years with diabetes mellitus and 1 additional risk factor. Randomization required fasting triglycerides ≥150 mg/dL and <500 mg/dL and LDL‐C >40 mg/dL and ≤100 mg/dL with stable statin (± ezetimibe) ≥4 weeks prior to qualifying measurements. The primary endpoint is a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary endpoint is the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Several secondary, tertiary, and exploratory endpoints will be assessed. Approximately 8000 patients have been randomized at approximately 470 centers worldwide. Follow‐up will continue in this event‐driven trial until approximately 1612 adjudicated primary‐efficacy endpoint events have occurred. |
| Author | Murphy, Sabina A. Jacobson, Terry A. Ballantyne, Christie M. Braeckman, Rene A. Steg, Ph. Gabriel Brinton, Eliot A. Soni, Paresh N. Juliano, Rebecca A. Doyle, Ralph T. Miller, Michael Ketchum, Steven B. Bhatt, Deepak L. Tardif, Jean‐Claude |
| AuthorAffiliation | 1 Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School Boston Massachusetts 8 Amarin Pharma Inc. Bedminster New Jersey 11 TIMI Study Group, Cardiovascular Division, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts 5 Office of Health Promotion and Disease Prevention, Department of Medicine Emory University School of Medicine Atlanta Georgia 12 Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention Methodist DeBakey Heart and Vascular Center Houston Texas 4 Utah Foundation for Biomedical Research, and Utah Lipid Center Salt Lake City 10 KemPharm, Inc., Celebration Florida 3 NHLI, Imperial College Royal Brompton Hospital London United Kingdom 6 Department of Medicine University of Maryland School of Medicine Baltimore 7 Montreal Heart Institute Université de Montréal Québec Canada 2 FACT (French Alliance for Cardiovascular Trials), an F‐CRIN network, Département Hospitalo‐Univ |
| AuthorAffiliation_xml | – name: 12 Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention Methodist DeBakey Heart and Vascular Center Houston Texas – name: 3 NHLI, Imperial College Royal Brompton Hospital London United Kingdom – name: 10 KemPharm, Inc., Celebration Florida – name: 9 Albireo Pharma Boston Massachusetts – name: 2 FACT (French Alliance for Cardiovascular Trials), an F‐CRIN network, Département Hospitalo‐Universitaire FIRE, AP‐HP, Hôpital Bichat Université Paris‐Diderot, INSERM U‐1148 Paris France – name: 4 Utah Foundation for Biomedical Research, and Utah Lipid Center Salt Lake City – name: 5 Office of Health Promotion and Disease Prevention, Department of Medicine Emory University School of Medicine Atlanta Georgia – name: 8 Amarin Pharma Inc. Bedminster New Jersey – name: 6 Department of Medicine University of Maryland School of Medicine Baltimore – name: 11 TIMI Study Group, Cardiovascular Division, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts – name: 1 Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School Boston Massachusetts – name: 7 Montreal Heart Institute Université de Montréal Québec Canada |
| Author_xml | – sequence: 1 givenname: Deepak L. orcidid: 0000-0002-1278-6245 surname: Bhatt fullname: Bhatt, Deepak L. organization: Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School – sequence: 2 givenname: Ph. Gabriel surname: Steg fullname: Steg, Ph. Gabriel organization: Royal Brompton Hospital – sequence: 3 givenname: Eliot A. surname: Brinton fullname: Brinton, Eliot A. organization: Utah Foundation for Biomedical Research, and Utah Lipid Center – sequence: 4 givenname: Terry A. surname: Jacobson fullname: Jacobson, Terry A. organization: Emory University School of Medicine – sequence: 5 givenname: Michael surname: Miller fullname: Miller, Michael organization: University of Maryland School of Medicine – sequence: 6 givenname: Jean‐Claude surname: Tardif fullname: Tardif, Jean‐Claude organization: Université de Montréal – sequence: 7 givenname: Steven B. surname: Ketchum fullname: Ketchum, Steven B. organization: Amarin Pharma Inc – sequence: 8 givenname: Ralph T. surname: Doyle fullname: Doyle, Ralph T. organization: Amarin Pharma Inc – sequence: 9 givenname: Sabina A. surname: Murphy fullname: Murphy, Sabina A. organization: Brigham and Women's Hospital and Harvard Medical School – sequence: 10 givenname: Paresh N. surname: Soni fullname: Soni, Paresh N. organization: Albireo Pharma – sequence: 11 givenname: Rene A. surname: Braeckman fullname: Braeckman, Rene A. organization: KemPharm, Inc., Celebration – sequence: 12 givenname: Rebecca A. surname: Juliano fullname: Juliano, Rebecca A. organization: Amarin Pharma Inc – sequence: 13 givenname: Christie M. surname: Ballantyne fullname: Ballantyne, Christie M. organization: Methodist DeBakey Heart and Vascular Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28294373$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc1qGzEUhUVJSZw0i75AGegmXTgZ_cxI6qJQptPWYCgYZy00khwryCNHmnHwLo8QyBvmSaKJndKGdnW53O8cjnSOwUHrWwPAe5ifwzxHF8qpc4RKjt6AEeQYjRnF9ACMcljmY44YPwLHMV4nNGcIH4IjxBAnmOIRuJnJzvpWOpPJVmfaRHvVZn6Rzepvl1X9eHc_mX_OZkb3auCGSyWDtn4jo-qdDFm9MW0Xs1vbLbOJ8lGu057V3XLrHu8eJm1nwkAM4nmw0r0DbxfSRXO6nyfg8ns9r36Op79-TKqv07EiJD0BkqIoFIMFLJqmKSnkkmttlEaY6sYgUnDOFow2Zd6okmjdlAaVECnCC4MxxCfgy8533Tcro1XKEKQT62BXMmyFl1b8fWntUlz5jSgwLzFhyeBsbxD8TW9iJ1Y2KuOcbI3vo4CMUlYginhCP75Cr30f0q8OFEOEckhQoj78meh3lJc2EnCxA1TwMQazEMp2z_2kgNYJmIuhb5H6Fs99J8WnV4oX03-xe_db68z2_6CoptVO8QRD6LvX |
| CitedBy_id | crossref_primary_10_1093_eurheartj_ehz321 crossref_primary_10_1016_j_jacl_2022_05_067 crossref_primary_10_1097_MOL_0000000000000465 crossref_primary_10_1161_CIRCOUTCOMES_118_004584 crossref_primary_10_1186_s12933_020_0991_1 crossref_primary_10_3389_fcvm_2025_1597062 crossref_primary_10_1007_s11883_019_0762_1 crossref_primary_10_1016_j_chemphyslip_2018_01_002 crossref_primary_10_1016_j_mayocp_2023_11_026 crossref_primary_10_1097_IAE_0000000000003465 crossref_primary_10_1097_MS9_0000000000003061 crossref_primary_10_1016_j_ajpc_2022_100345 crossref_primary_10_1161_JAHA_121_022937 crossref_primary_10_3390_ijms20225549 crossref_primary_10_1007_s10557_023_07519_z crossref_primary_10_1161_CIR_0000000000000709 crossref_primary_10_1016_j_jacc_2018_03_541 crossref_primary_10_1016_j_jlr_2021_100106 crossref_primary_10_1016_j_prostaglandins_2019_106407 crossref_primary_10_1016_j_numecd_2025_104199 crossref_primary_10_1002_ejlt_201800029 crossref_primary_10_1038_s41581_018_0072_9 crossref_primary_10_1089_jwh_2017_6757 crossref_primary_10_1007_s41745_022_00346_5 crossref_primary_10_1097_MOL_0000000000000455 crossref_primary_10_3389_fnut_2024_1325099 crossref_primary_10_1093_eurheartj_ehz455 crossref_primary_10_1016_j_amjcard_2018_06_029 crossref_primary_10_1016_j_vph_2023_107175 crossref_primary_10_1002_2327_6924_12535 crossref_primary_10_1016_j_jacl_2017_08_009 crossref_primary_10_1016_j_jacl_2019_08_001 crossref_primary_10_15829_1728_8800_2023_3382 crossref_primary_10_1161_CIRCULATIONAHA_121_055560 crossref_primary_10_1016_j_jacc_2020_09_005 crossref_primary_10_1002_prp2_584 crossref_primary_10_1002_clc_22856 crossref_primary_10_3390_biomedicines9101466 crossref_primary_10_1016_j_pcad_2018_03_006 crossref_primary_10_1016_j_cct_2020_106124 crossref_primary_10_1016_j_ihj_2024_01_010 crossref_primary_10_1016_j_pcad_2021_08_003 crossref_primary_10_1016_j_jacc_2019_08_1016 crossref_primary_10_1016_j_jacc_2021_08_009 crossref_primary_10_1161_CIRCULATIONAHA_117_032318 crossref_primary_10_1016_j_mayocp_2019_03_028 crossref_primary_10_1097_01_NPR_0000526627_04268_80 crossref_primary_10_1161_ATVBAHA_117_309493 crossref_primary_10_1002_clc_23055 crossref_primary_10_1016_j_atherosclerosis_2021_11_022 crossref_primary_10_1186_s13098_025_01868_5 crossref_primary_10_1161_ATVBAHA_119_313286 crossref_primary_10_1161_JAHA_121_026756 crossref_primary_10_1182_bloodadvances_2020002493 crossref_primary_10_1161_JAHA_120_020377 crossref_primary_10_1007_s12170_019_0603_3 crossref_primary_10_1016_j_jacc_2024_02_016 crossref_primary_10_1016_j_jacc_2021_06_011 crossref_primary_10_1016_j_tcm_2021_04_007 crossref_primary_10_1186_s12872_020_01445_w crossref_primary_10_1177_08830738211015051 crossref_primary_10_1097_HCO_0000000000001136 crossref_primary_10_1111_dme_13667 crossref_primary_10_1093_eurheartj_ehaf074 crossref_primary_10_1093_ehjcvp_pvac045 crossref_primary_10_1177_10742484211002943 crossref_primary_10_5937_mckg53_21900 crossref_primary_10_1007_s40256_018_0312_1 crossref_primary_10_1016_j_heliyon_2022_e11530 crossref_primary_10_1038_s41569_019_0169_2 crossref_primary_10_3390_jcm14020643 crossref_primary_10_17925_HI_2021_15_1_7 crossref_primary_10_1016_j_jacc_2019_06_043 crossref_primary_10_2217_fca_2020_0106 crossref_primary_10_1097_HCO_0000000000000678 crossref_primary_10_1161_CIRCULATIONAHA_119_044440 crossref_primary_10_3390_nu16244318 crossref_primary_10_1161_JAHA_123_032413 crossref_primary_10_1016_j_semnephrol_2018_05_007 crossref_primary_10_1111_cts_13366 crossref_primary_10_1093_eurjpc_zwae003 crossref_primary_10_3390_md21110549 crossref_primary_10_1016_j_atherosclerosis_2019_08_014 crossref_primary_10_1016_j_jacc_2019_02_032 crossref_primary_10_1161_JAHA_121_024999 crossref_primary_10_1093_ehjopen_oead114 crossref_primary_10_3390_ijms19041197 crossref_primary_10_1210_jc_2018_00470 crossref_primary_10_1016_j_addr_2020_05_008 crossref_primary_10_1016_j_ijcard_2021_08_031 crossref_primary_10_1080_00325481_2017_1385365 crossref_primary_10_1016_j_ahj_2021_01_018 crossref_primary_10_1056_NEJMoa1811403 crossref_primary_10_1002_cpt_1114 crossref_primary_10_1016_j_jacl_2022_11_002 crossref_primary_10_1093_eurheartj_ehz778 crossref_primary_10_1016_j_jacc_2022_02_035 crossref_primary_10_3390_ijms24044066 crossref_primary_10_1161_JAHA_124_038656 crossref_primary_10_1002_clc_23220 crossref_primary_10_1080_14740338_2021_1954158 crossref_primary_10_1016_j_phanu_2024_100400 crossref_primary_10_1016_j_ebiom_2020_102883 crossref_primary_10_1080_13543784_2019_1696772 crossref_primary_10_1161_CIRCULATIONAHA_121_056290 crossref_primary_10_1093_ehjcvp_pvaa118 crossref_primary_10_1016_j_plefa_2021_102337 crossref_primary_10_3390_md17060374 crossref_primary_10_3389_fphar_2019_00205 crossref_primary_10_1111_dom_13921 crossref_primary_10_1097_HCO_0000000000000415 crossref_primary_10_5937_afmnai39_34287 crossref_primary_10_3390_nu10070864 crossref_primary_10_1093_ehjcvp_pvae030 crossref_primary_10_1016_j_jacc_2018_04_061 crossref_primary_10_1007_s11010_020_03965_7 crossref_primary_10_1016_j_cpcardiol_2023_102066 crossref_primary_10_1161_JAHA_117_008189 crossref_primary_10_1093_nutrit_nuad158 crossref_primary_10_1161_JAHA_118_008740 crossref_primary_10_7759_cureus_47365 crossref_primary_10_1093_eurheartj_suaa116 crossref_primary_10_1080_17460441_2022_2104247 crossref_primary_10_1093_eurheartj_suaa119 crossref_primary_10_3389_fcvm_2023_1094100 crossref_primary_10_1007_s11892_018_1087_0 crossref_primary_10_1111_1753_0407_12789 crossref_primary_10_1161_CIRCULATIONAHA_120_050276 crossref_primary_10_1159_000504022 crossref_primary_10_1007_s11883_017_0700_z crossref_primary_10_1016_j_bbalip_2018_04_012 crossref_primary_10_1007_s00394_020_02413_y crossref_primary_10_1093_eurheartj_ehad889 crossref_primary_10_1056_NEJMoa1812792 crossref_primary_10_1111_dom_13537 crossref_primary_10_1016_j_jjcc_2022_02_011 crossref_primary_10_1007_s11886_023_01926_2 crossref_primary_10_1136_bmjopen_2022_061360 crossref_primary_10_1016_j_bbadis_2018_02_006 crossref_primary_10_1016_j_vph_2017_02_004 crossref_primary_10_3390_nu16234195 crossref_primary_10_1210_clinem_dgaa674 crossref_primary_10_1016_j_jacl_2018_07_007 crossref_primary_10_1111_jth_15184 crossref_primary_10_1017_S0029665118002902 |
| Cites_doi | 10.1093/eurheartj/eht055 10.1056/NEJMoa1300955 10.1056/NEJMoa1107579 10.1016/j.amjcard.2011.04.015 10.1056/NEJMoa1001282 10.1136/heartjnl-2013-305257 10.1016/S0140-6736(99)07072-5 10.1016/j.atherosclerosis.2014.02.025 10.1016/j.amjcard.2012.05.031 10.1056/NEJMoa1003603 10.1056/NEJMoa1203859 10.1007/s40256-012-0002-3 10.2217/clp.11.54 10.1016/j.ijcard.2016.11.105 10.1016/j.jacc.2013.07.023 10.1161/CIRCRESAHA.115.306249 10.1016/j.jacl.2016.02.008 10.1016/j.atherosclerosis.2008.06.003 10.1093/eurheartj/ehu500 10.1056/NEJMoa1205409 10.1161/CIRCOUTCOMES.115.002104 10.1016/S0140-6736(07)60527-3 10.1161/01.CIR.102.1.21 10.1136/bmj.c6273 10.1253/circj.CJ-15-0813 10.1056/NEJM199908053410604 10.1016/j.prostaglandins.2016.07.007 10.1016/j.atherosclerosis.2016.08.005 10.1016/S0140-6736(05)67667-2 10.1161/01.CIR.85.1.37 10.1056/NEJM198711123172001 10.1016/S0140-6736(08)61239-8 10.1161/CIRCULATIONAHA.110.948562 |
| ContentType | Journal Article |
| Copyright | 2017 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc. 2017 Wiley Periodicals, Inc. |
| Copyright_xml | – notice: 2017 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc. – notice: 2017 Wiley Periodicals, Inc. |
| CorporateAuthor | on behalf of the REDUCE‐IT Investigators REDUCE-IT Investigators |
| CorporateAuthor_xml | – name: on behalf of the REDUCE‐IT Investigators – name: REDUCE-IT Investigators |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 5PM |
| DOI | 10.1002/clc.22692 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Rationale and Design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl ‐ Intervention Trial |
| EISSN | 1932-8737 |
| EndPage | 148 |
| ExternalDocumentID | PMC5396348 4321325397 28294373 10_1002_clc_22692 CLC22692 |
| Genre | article Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Journal Article |
| GrantInformation_xml | – fundername: Amarin Pharma Inc |
| GroupedDBID | --- .GJ 05W 0R~ 10A 1OB 1OC 24P 29B 31~ 4.4 50Y 51W 51X 52M 52N 52P 52R 52S 52X 53G 5GY 5RE 5VS 7PT 7X7 8-1 8FI 8FJ 8UM AAFWJ AAMMB AAZKR ABCQN ABEML ABOCM ABUWG ACCMX ACSCC ACXQS ADBBV ADKYN ADZMN AEFGJ AENEX AFBPY AFKRA AFPKN AGXDD AHMBA AIDQK AIDYY ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AVUZU BCNDV BENPR BFHJK BY8 CCPQU CS3 DU5 EBS EJD EMOBN F5P FYUFA G-S GODZA GROUPED_DOAJ HF~ HMCUK HYE HZ~ IAO IHR INH ITC J0M LAW LC2 LC3 LH4 LW6 MY~ O9- OIG OK1 P6G PHGZM PHGZT PIMPY PQQKQ PUEGO Q11 QRW RPM RX1 SUPJJ TR2 UKHRP WIN WQJ WXI XG1 XV2 ZGI ZXP AAYXX AFFHD CITATION AAHHS ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE ALIPV CGR CUY CVF ECM EIF NPM K9. 7X8 5PM |
| ID | FETCH-LOGICAL-c4432-14555c81515bbb6719a9ddecd237dbe245998f87b60bc64ddb6e2612c495e3313 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 164 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000398582600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0160-9289 1932-8737 |
| IngestDate | Tue Sep 30 17:06:05 EDT 2025 Thu Sep 04 16:16:21 EDT 2025 Tue Oct 07 06:01:59 EDT 2025 Thu Apr 03 07:06:56 EDT 2025 Tue Nov 18 21:32:42 EST 2025 Sat Nov 29 02:18:21 EST 2025 Sun Sep 21 06:19:05 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Clinical trials General clinical cardiology/adult Lipidology |
| Language | English |
| License | Attribution-NonCommercial http://creativecommons.org/licenses/by-nc/4.0 2017 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4432-14555c81515bbb6719a9ddecd237dbe245998f87b60bc64ddb6e2612c495e3313 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 Funding information The trial is sponsored by Amarin Pharma Inc. |
| ORCID | 0000-0002-1278-6245 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fclc.22692 |
| PMID | 28294373 |
| PQID | 1882479142 |
| PQPubID | 946375 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5396348 proquest_miscellaneous_1877852729 proquest_journals_1882479142 pubmed_primary_28294373 crossref_citationtrail_10_1002_clc_22692 crossref_primary_10_1002_clc_22692 wiley_primary_10_1002_clc_22692_CLC22692 |
| PublicationCentury | 2000 |
| PublicationDate | March 2017 |
| PublicationDateYYYYMMDD | 2017-03-01 |
| PublicationDate_xml | – month: 03 year: 2017 text: March 2017 |
| PublicationDecade | 2010 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States – name: Hoboken |
| PublicationTitle | Clinical cardiology (Mahwah, N.J.) |
| PublicationTitleAlternate | Clin Cardiol |
| PublicationYear | 2017 |
| Publisher | Wiley Periodicals, Inc John Wiley & Sons, Inc |
| Publisher_xml | – name: Wiley Periodicals, Inc – name: John Wiley & Sons, Inc |
| References | 2015; 36 2007; 369 2013; 62 2013; 368 2010; 363 2010; 341 2016; 10 1999; 341 2010; 122 2010; 362 2014; 371 2016; 125 2008; 200 2012; 367 2011; 6 2014; 234 2012; 110 2011; 108 2000; 102 2013; 13 2016; 118 2005; 366 2013; 34 1987; 317 2017 2016; 253 1999; 354 2016; 80 2014; 100 2011; 365 2008; 372 2016; 9 1992; 85 2017; 228 e_1_2_6_32_1 e_1_2_6_10_1 e_1_2_6_31_1 e_1_2_6_30_1 e_1_2_6_19_1 e_1_2_6_13_1 e_1_2_6_36_1 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_12_1 e_1_2_6_33_1 e_1_2_6_17_1 e_1_2_6_18_1 e_1_2_6_39_1 e_1_2_6_15_1 e_1_2_6_38_1 e_1_2_6_16_1 e_1_2_6_37_1 e_1_2_6_21_1 e_1_2_6_20_1 e_1_2_6_9_1 e_1_2_6_8_1 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_24_1 e_1_2_6_3_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_22_1 e_1_2_6_29_1 e_1_2_6_28_1 e_1_2_6_27_1 e_1_2_6_26_1 |
| References_xml | – volume: 13 start-page: 37 year: 2013 end-page: 46 article-title: Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies publication-title: Am J Cardiovasc Drugs. – volume: 34 start-page: 1279 year: 2013 end-page: 1291 article-title: HPS2‐THRIVE randomized placebo‐controlled trial in 25 673 high‐risk patients of ER niacin/laropiprant: trial design, pre‐specified muscle and liver outcomes, and reasons for stopping study treatment publication-title: Eur Heart J – volume: 365 start-page: 2255 year: 2011 end-page: 2267 article-title: Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy publication-title: N Engl J Med – volume: 80 start-page: 450 year: 2016 end-page: 460 article-title: Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound publication-title: Circ J. – volume: 125 start-page: 57 year: 2016 end-page: 64 article-title: Icosapent ethyl: eicosapentaenoic acid concentration and triglyceride‐lowering effects across clinical studies publication-title: Prostag Oth Lipid M. – volume: 62 start-page: 1580 year: 2013 end-page: 1584 article-title: Relationship of lipoproteins to cardiovascular events: the AIM‐HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes) publication-title: J Am Coll Cardiol. – volume: 317 start-page: 1237 year: 1987 end-page: 1245 article-title: Helsinki Heart Study: primary‐prevention trial with gemfibrozil in middle‐aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease publication-title: N Engl J Med – volume: 118 start-page: 547 year: 2016 end-page: 563 article-title: Triglyceride‐rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology publication-title: Circ Res. – volume: 368 start-page: 1800 year: 2013 end-page: 1808 article-title: n‐3 fatty acids in patients with multiple cardiovascular risk factors [published correction appears in . 2013;368:2146] publication-title: N Engl J Med – volume: 110 start-page: 984 year: 2012 end-page: 992 article-title: Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin‐treated patients with persistent high triglycerides (from the ANCHOR study) publication-title: Am J Cardiol. – volume: 362 start-page: 1563 year: 2010 end-page: 1574 article-title: Effects of combination lipid therapy in type 2 diabetes mellitus [published correction appears in . 2010;362:1748] publication-title: N Engl J Med – volume: 369 start-page: 1090 year: 2007 end-page: 1098 article-title: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open‐label, blinded endpoint analysis publication-title: Lancet – volume: 341 start-page: c6273 year: 2010 article-title: Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial publication-title: BMJ. – volume: 10 start-page: 635.e1 year: 2016 end-page: 645.e1 article-title: Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on plasma apolipoprotein C‐III levels in patients from the MARINE and ANCHOR studies publication-title: J Clin Lipidol – volume: 253 start-page: 81 year: 2016 end-page: 87 article-title: Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant‐like particle cholesterol from the MARINE and ANCHOR studies publication-title: Atherosclerosis. – volume: 341 start-page: 410 year: 1999 end-page: 418 article-title: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high‐density lipoprotein cholesterol. Veterans Affairs High‐Density Lipoprotein Cholesterol Intervention Trial Study Group publication-title: N Engl J Med – volume: 366 start-page: 1849 year: 2005 end-page: 1861 article-title: Effects of long‐term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial publication-title: Lancet – volume: 122 start-page: 2152 year: 2010 end-page: 2159 article-title: OMEGA, a randomized, placebo‐controlled trial to test the effect of highly purified omega‐3 fatty acids on top of modern guideline‐adjusted therapy after myocardial infarction publication-title: Circulation. – volume: 102 start-page: 21 year: 2000 end-page: 27 article-title: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Bezafibrate Infarction Prevention (BIP) study publication-title: Circulation. – volume: 6 start-page: 723 year: 2011 end-page: 729 article-title: Treatment with ω‐3 fatty acids reduces serum C‐reactive protein concentration publication-title: Clin Lipidol. – volume: 36 start-page: 774 year: 2015 end-page: 776 article-title: Triglycerides on the rise: should we swap seats on the seesaw? publication-title: Eur Heart J. – volume: 354 start-page: 447 year: 1999 end-page: 455 article-title: Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‐Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico [published corrections appear in . 2001;357:642 and 2007;369:106] publication-title: Lancet – volume: 371 start-page: 203 year: 2014 end-page: 212 article-title: Effects of extended‐release niacin with laropiprant in high‐risk patients publication-title: N Engl J Med – volume: 200 start-page: 135 year: 2008 end-page: 140 article-title: Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub‐analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS) publication-title: Atherosclerosis – volume: 234 start-page: 114 year: 2014 end-page: 119 article-title: Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin‐cap fibroatheroma publication-title: Atherosclerosis. – volume: 85 start-page: 37 year: 1992 end-page: 45 article-title: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment publication-title: Circulation. – volume: 372 start-page: 1223 year: 2008 end-page: 1230 article-title: Effect of n‐3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double‐blind, placebo‐controlled trial publication-title: Lancet – volume: 9 start-page: 100 year: 2016 end-page: 108 article-title: Elevated triglyceride level is independently associated with increased all‐cause mortality in patients with established coronary heart disease: twenty‐two‐year follow‐up of the Bezafibrate Infarction Prevention Study and Registry [published correction appears in . 2016;9:613] publication-title: Circ Cardiovasc Qual Outcomes – volume: 100 start-page: 530 year: 2014 end-page: 533 article-title: Omega‐3 fatty acids, atherosclerosis progression and cardiovascular outcomes in recent trials: new pieces in a complex puzzle publication-title: Heart. – volume: 108 start-page: 682 year: 2011 end-page: 690 article-title: Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi‐center, Placebo‐controlled, Randomized, Double‐blind, 12‐week study with an open‐label Extension [MARINE] trial) publication-title: Am J Cardiol. – volume: 367 start-page: 309 year: 2012 end-page: 318 article-title: n‐3 fatty acids and cardiovascular outcomes in patients with dysglycemia publication-title: N Engl J Med – year: 2017 – volume: 363 start-page: 2015 year: 2010 end-page: 2026 article-title: n‐3 fatty acids and cardiovascular events after myocardial infarction publication-title: N Engl J Med – volume: 228 start-page: 173 year: 2017 end-page: 179 article-title: Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1‐year outcomes of a randomized controlled study publication-title: Int J Cardiol. – ident: e_1_2_6_13_1 doi: 10.1093/eurheartj/eht055 – ident: e_1_2_6_15_1 doi: 10.1056/NEJMoa1300955 – ident: e_1_2_6_16_1 doi: 10.1056/NEJMoa1107579 – ident: e_1_2_6_26_1 doi: 10.1016/j.amjcard.2011.04.015 – ident: e_1_2_6_7_1 doi: 10.1056/NEJMoa1001282 – ident: e_1_2_6_20_1 doi: 10.1136/heartjnl-2013-305257 – ident: e_1_2_6_18_1 doi: 10.1016/S0140-6736(99)07072-5 – ident: e_1_2_6_33_1 doi: 10.1016/j.atherosclerosis.2014.02.025 – ident: e_1_2_6_27_1 doi: 10.1016/j.amjcard.2012.05.031 – ident: e_1_2_6_37_1 – ident: e_1_2_6_14_1 – ident: e_1_2_6_21_1 doi: 10.1056/NEJMoa1003603 – ident: e_1_2_6_22_1 doi: 10.1056/NEJMoa1203859 – ident: e_1_2_6_30_1 doi: 10.1007/s40256-012-0002-3 – ident: e_1_2_6_31_1 doi: 10.2217/clp.11.54 – ident: e_1_2_6_39_1 – ident: e_1_2_6_34_1 doi: 10.1016/j.ijcard.2016.11.105 – ident: e_1_2_6_36_1 – ident: e_1_2_6_6_1 doi: 10.1016/j.jacc.2013.07.023 – ident: e_1_2_6_4_1 doi: 10.1161/CIRCRESAHA.115.306249 – ident: e_1_2_6_29_1 doi: 10.1016/j.jacl.2016.02.008 – ident: e_1_2_6_5_1 doi: 10.1016/j.atherosclerosis.2008.06.003 – ident: e_1_2_6_2_1 doi: 10.1093/eurheartj/ehu500 – ident: e_1_2_6_24_1 doi: 10.1056/NEJMoa1205409 – ident: e_1_2_6_3_1 doi: 10.1161/CIRCOUTCOMES.115.002104 – ident: e_1_2_6_17_1 doi: 10.1016/S0140-6736(07)60527-3 – ident: e_1_2_6_10_1 doi: 10.1161/01.CIR.102.1.21 – ident: e_1_2_6_25_1 doi: 10.1136/bmj.c6273 – ident: e_1_2_6_32_1 doi: 10.1253/circj.CJ-15-0813 – ident: e_1_2_6_8_1 doi: 10.1056/NEJM199908053410604 – ident: e_1_2_6_35_1 doi: 10.1016/j.prostaglandins.2016.07.007 – ident: e_1_2_6_28_1 doi: 10.1016/j.atherosclerosis.2016.08.005 – ident: e_1_2_6_38_1 – ident: e_1_2_6_9_1 doi: 10.1016/S0140-6736(05)67667-2 – ident: e_1_2_6_11_1 doi: 10.1161/01.CIR.85.1.37 – ident: e_1_2_6_12_1 doi: 10.1056/NEJM198711123172001 – ident: e_1_2_6_19_1 doi: 10.1016/S0140-6736(08)61239-8 – ident: e_1_2_6_23_1 doi: 10.1161/CIRCULATIONAHA.110.948562 |
| SSID | ssj0020823 |
| Score | 2.533791 |
| Snippet | Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have... Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol ( LDL ‐C)... Residual cardiovascular risk persists despite statins, yet outcome studies of lipid-targeted therapies beyond low-density lipoprotein cholesterol (LDL-C) have... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 138 |
| SubjectTerms | Cardiovascular Diseases - drug therapy Cardiovascular Diseases - epidemiology Clinical trials Dose-Response Relationship, Drug Double-Blind Method Eicosapentaenoic Acid - administration & dosage Eicosapentaenoic Acid - analogs & derivatives Female Follow-Up Studies France - epidemiology General clinical cardiology/adult Health risk assessment Heart attacks Humans Incidence Lipidology Low density lipoprotein Male Middle Aged Platelet Aggregation Inhibitors - administration & dosage Prospective Studies Quebec - epidemiology Risk Factors Time Factors Treatment Outcome Trial Designs Triglycerides United Kingdom - epidemiology United States - epidemiology |
| Title | Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fclc.22692 https://www.ncbi.nlm.nih.gov/pubmed/28294373 https://www.proquest.com/docview/1882479142 https://www.proquest.com/docview/1877852729 https://pubmed.ncbi.nlm.nih.gov/PMC5396348 |
| Volume | 40 |
| WOSCitedRecordID | wos000398582600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1932-8737 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0020823 issn: 0160-9289 databaseCode: WIN dateStart: 19780101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB5CWkovfT-2TYtaeujFxJZkS2pPZdnQhXYJy5buzVgPk0DwpnGSc35CoP8wv6QzstfNkhYKvRibGWNZmpFmNKNvAN6JIoQa3ePEWC8TKY1MbOVEkqeFry33QuY-FptQs5leLs3-Fnxcn4Xp8CGGDTfSjDhfk4JXtt39DRpKh5XRdjA4_97KMqGpbgOX-4O3RSGkDtg7TQy6FWtYoZTvDq9uLkY3LMybiZLXDdi4Au3d_6-2P4B7veHJPnWS8hC2QvMI7nztQ-uP4ce83xYMrGo88zGzg61qNqfiPJOri8vp4gObE9Ir8RFlvJHLyiaUOtky2tllU7dqq2N8ZhOUhKOri5_Ta8mVbEFi_wS-7U0W489JX48hcVIKnhCmee40mUDW2kJlpjI4OzrPhfI2cJmj71ZrZYvUukJ6b4tACGUOnbAgRCaewnazasJzYFwKabVIg_U1Gmx1lcpMGxsyroJxuRnB-_XAlK4HK6eaGUdlB7PMS-zCMnbhCN4OrMcdQsefmHbWo1v2StqWGXoXUplMIvnNQEb1ophJ1YTVGfEopXOOLsgInnXCMHyFgtCEDDUCtSEmAwNBd29SmsODCOGdC5z4pMbfjGLy94aX4y_jePPi31lfwl1OxkfMlNuB7dOTs_AKbrvz08P25HXUEryqpcbr9-nsF1ecGPY |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9RAEB9KFe2L37anVVfxwZfQZHeTzRZf5LjS4PWQ48S-hexHsFByba_1uX-C4H_Yv6Qzm1zsUQXBt4SdkGR3Zna-9jcA70XmfY3ucaSNk5GUWkamsiJK48zVhjshUxeaTajJJD881F_W4OPyLEyLD9EH3Egygr4mAaeA9M5v1FA6rYzGg0YFfEeioUGNG74Vk97dohxSi-wdRxr9iiWuUMx3-kdXd6NbJubtSsmbFmzYgvYe_t_HP4IHnenJPrW88hjWfPME7h10yfWncDrtAoOeVY1jLtR2sHnNptSeZ3R1-bOY7bIpYb0SHY0MV6pZ2YiKJxeMYrussPNFdYL3bIS8cHx1-au4UV7JZsT4z-Dr3mg23I-6jgyRlVLwiFDNU5uTEWSMyVSiK4360ToulDOeyxS9tzpXJouNzaRzJvOEUWbRDfNCJOI5rDfzxm8B41JIk4vYG1ejyVZXsUxybXzCldc21QP4sFyZ0nZw5dQ147hsgZZ5iVNYhikcwLue9KTF6PgT0fZyectOTBdlgv6FVDqROPy2H0YBo6xJ1fj5BdEolaccnZABbLbc0L-F0tCEDTUAtcInPQGBd6-ONEffA4h3KlD1yRx_M_DJ3z-8HI6H4eLFv5O-gfv7s4NxOS4mn1_CBidTJNTNbcP6-dmFfwV37Y_zo8XZ6yAy13gMG1c |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fa9RAEB9KleKL1v9Xq67igy-hye4mmxVfynmHh_U4jhP6FrJ_Qgsld_baPvcjFPoN-0mc2eRijyoIviXMhCS7M7MzO7O_AfggMu8rDI8jbZyMpNQyMqUVURpnrjLcCZm60GxCjcf54aGebMDn1VmYBh-i23AjzQj2mhTcL1y19xs1lE4ro_Og0QDfk6lKSKa5nHThFuWQGmTvONIYV6xwhWK-1z26vhrdcTHvVkre9mDDEjR89H8fvw0PW9eT7Tey8hg2fP0Etr63yfWn8HPabgx6VtaOuVDbweYVm1J7nsHN5dVo9olNCeuV-IjSX6tmZQMqnlwy2ttlIztflgu8ZwOUhZOby-vRrfJKNiPBfwY_hoNZ_2vUdmSIrJSCR4RqntqcnCBjTIZjXmq0j9ZxoZzxXKYYvVW5MllsbCadM5knjDKLYZgXIhHPYbOe1_4lMC6FNLmIvXEVumxVGcsk18YnXHltU92Dj6uZKWwLV05dM06KBmiZFziERRjCHrzvWBcNRsefmHZX01u0arosEowvpNKJRPK7jowKRlmTsvbzc-JRKk85BiE9eNFIQ_cWSkMTNlQP1JqcdAwE3r1OqY-PAoh3KtD0yRx_M8jJ3z-86B_0w8XOv7O-ha3Jl2FxMBp_ewUPOHkioWxuFzbPTs_9a7hvL86Ol6dvgsb8AlAjGm4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rationale+and+design+of+REDUCE%E2%80%90IT+%3A+Reduction+of+Cardiovascular+Events+with+Icosapent+Ethyl%E2%80%93Intervention+Trial&rft.jtitle=Clinical+cardiology+%28Mahwah%2C+N.J.%29&rft.au=Bhatt%2C+Deepak+L.&rft.au=Steg%2C+Ph.+Gabriel&rft.au=Brinton%2C+Eliot+A.&rft.au=Jacobson%2C+Terry+A.&rft.date=2017-03-01&rft.issn=0160-9289&rft.eissn=1932-8737&rft.volume=40&rft.issue=3&rft.spage=138&rft.epage=148&rft_id=info:doi/10.1002%2Fclc.22692&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_clc_22692 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0160-9289&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0160-9289&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0160-9289&client=summon |